Caring Brands Inc. announced an exclusive worldwide license agreement with Itonis Inc. for Emesyl, an OTC nausea relief product.
The agreement grants Caring Brands full rights to commercialize Emesyl and manage all manufacturing activities.
The global market for nausea treatment and related therapies is projected to exceed USD 6.23 billion by 2025, highlighting the significance of the Emesyl license.
Licensing Agreement
Caring Brands secures exclusive rights to manufacture, market, and distribute Emesyl worldwide from Itonis Inc.
Market Potential
Projected growth in the global nausea treatment market emphasizes the commercial opportunity of the Emesyl license.
Strategic Milestone
The agreement aligns with Caring Brands' long-term strategy to expand its health and wellness portfolio with recognized products like Emesyl.
- The agreement includes a royalty structure based on future net sales and potential equity in Itonis for Caring Brands tied to revenue milestones.
- Caring Brands plans to provide updates on product timelines, manufacturing progress, and commercial rollout as the initiatives progress.
Caring Brands' exclusive license for Emesyl marks a significant step in expanding its product portfolio. The strategic agreement aligns with the company's vision for growth and market expansion in the health and wellness sector.